Remimazolam TIVA-Flumazenil Antagonism in Short-duration ENT Surgeries

Different Bispectral Index Guided Remimazolam Total Intravenous Anesthesia-flumazenil Antagonism in Short-duration Ear Nose Throat Surgeries: A Retrospective Cohort Study

This study plans to categorize patients who underwent short-duration ENT surgeries with remimazolam TIVA combined with flumazenil antagonism based on whether their intraoperative BIS values were maintained below 60.

This study plans to categorize patients who underwent short-duration ENT surgeries with remimazolam TIVA combined with flumazenil antagonism into two groups based on whether their intraoperative BIS values were maintained below 60. It aims to compare the differences in postoperative recovery quality between the groups, thereby providing evidence-based support for determining the optimal BIS target range during remimazolam TIVA.

Inclusion Criteria:

• Age 18-65 years
• ASA I-III
• Underwent short-duration ENT surgery
• Underwent remimazolam TIVA combined with flumazenil antagonism.
• Continuous intraoperative BIS monitoring

Exclusion Criteria:

• Comorbid severe underlying diseases
• Intraoperative BIS data were missing or incompletely recorded
• Severe lack of medical records